Time trends in primary therapy and relative survival of diffuse large B-cell lymphoma by stage: a nationwide, population-based study in the Netherlands, 1989–2018

Autor: Müjde Durmaz, Otto Visser, Eduardus F. M. Posthuma, Rolf E. Brouwer, Djamila E. Issa, Daphne de Jong, King H. Lam, Nicole M. A. Blijlevens, Josée M. Zijlstra, Martine E. D. Chamuleau, Pieternella J. Lugtenburg, Marie José Kersten, Avinash G. Dinmohamed

Publikováno v: Blood Cancer Journal, Vol 12, Iss 3, Pp 1-11 (2022)

Abstract It is unclear whether survival in diffuse large B-cell lymphoma (DLBCL) continues to increase in an era where rituximab-containing chemotherapy reigns for almost two decades. Therefore, we evaluated trends in primary therapy and relative sur

Externí odkaz: https://doaj.org/article/7115e3dd9f164bb78f75d59e6460bd0e

Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)

Autor: Coreline N. Burggraaff, Gregor Verhoef, Otto S. Hoekstra, Marie José Kersten, Lidwine W. Tick, Mels Hoogendoorn, Margreet Oosterveld, Daphne de Jong, Nicole C. H. P. van der Burg-de Graauw, Marinus van Marwijk Kooy, Matthijs H Silbermann, Aart Beeker, Marjolein van der Poel, Bart de Keizer, Eva de Jongh, Jeanette K. Doorduijn, Harry R. Koene, Thomas Stauffer Larsen, Memis Y Bilgin, Lara H Böhmer, Joost W. J. van Esser, Peter de Nully Brown, Marcel Nijland, Maria B.L. Leijs, J.F.M. Pruijt, Anne I.J. Arens, Josée M Zijlstra-Baalbergen, Pieternella J. Lugtenburg, Kon-Siong G. Jie, Rolf E. Brouwer, King H. Lam, Rob Fijnheer, Bronno van der Holt, Francesco d'Amore

Publikováno v: Journal of Clinical Oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(29). American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma : A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of clinical oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-chop with early rituximab intensification for diffuse large b-cell lymphoma : A randomized phase iii trial of the hovon and the nordic lymphoma group (hovon-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of Clinical Oncology, 38, 29, pp. 3377-3387
Journal of Clinical Oncology, 38(29), 3377-3387. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(29):38, 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38, 3377-3387
Lugtenburg, P J, de Nully Brown, P, van der Holt, B, D'Amore, F A, Koene, H R, de Jongh, E, Fijnheer, R, van Esser, J W, Böhmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, van der Burg-de Graauw, N C, Oosterveld, M, Jie, K-S G, Larsen, T S, van der Poel, M W, Leijs, M B, Silbermann, M H, van Marwijk Kooy, M, Beker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, de Keizer, B, Arens, A I, de Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, 38, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418, https://doi.org/DOI: 10.1200/JCO.19.03418

PURPOSE Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). This randomized trial assessed whether rituximab i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c7540ecb6cafd809a54c75ab38ea46d
https://cris.maastrichtuniversity.nl/en/publications/14069863-94fd-45a6-a6a0-7e5cfcc2608a

Peripheral Photopenia on Whole-Body PET/CT Imaging With 18F-FDG in Patients With Compartment Syndrome and Mesenteric Venous Thrombosis

Autor: Rolf E. Brouwer, Peter L. Tangkau, Marc R J Ten Broek, Stijn van Esser, Erik T. te Beek

Publikováno v: Clinical Nuclear Medicine. 45:1007-1009

We present 2 cases that demonstrate photopenia in peripheral areas on whole-body PET/CT imaging with F-FDG as a sign of absent perfusion with severe short-term complications. The scan of the first patient shows photopenia in the right ankle and foot,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0603e1730e3309574df8ce181e6157b
https://doi.org/10.1097/rlu.0000000000003315

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS

Autor: Markus G. Manz, Harm Sinnige, Marie-Christiane Vekemans, Jürgen Kuball, Yves Chalandon, Dominik Heim, Lidwine W. Tick, Thomas Pabst, Peter E. Westerweel, Marjolein van der Poel, Dimitri Breems, Jeroen Janssen, Marie-Cecile Legdeur, Ine Moors, Carlos Graux, Rolf E. Brouwer, Wim Terpstra, Danielle van Lammeren-Venema, Dries Deeren, Johan Maertens, Okke de Weerdt, Peter A. von dem Borne, Marinus van Marwijk Kooy, Marten R. Nijziel, Arjan A. van de Loosdrecht, Mojca Jongen-Lavrencic, Mels Hoogendoorn, Florence Van Obbergh, Yvette van Norden, Anna Efthymiou, Bjørn-Tore Gjertsen, Georg Stussi, Gert J. Ossenkoppele, Margriet Oosterveld, Bart J. Biemond, Asiong Jie, Mario Bargetzi, Edo Vellenga, Marjolein van der Klift, Aurélie Jaspers, Saskia K. Klein, Olivier Spertini, Walter J.F.M. van der Velden, Urs Hess, Bob Löwenberg, Michael Gregor

Publikováno v: Cancers, vol. 13, no. 4, pp. 672
Cancers, Vol. 13, No 4 (2021) P. 672
Cancers
Volume 13
Issue 4
Cancers, 13
Janssen, J, Löwenberg, B, Manz, M, Bargetzi, M, Biemond, B, von dem Borne, P, Breems, D, Brouwer, R, Chalandon, Y, Deeren, D, Efthymiou, A, Gjertsen, B T, Graux, C, Gregor, M, Heim, D, Hess, U, Hoogendoorn, M, Jaspers, A, Jie, A, Jongen-Lavrencic, M, Klein, S, van der Klift, M, Kuball, J, van Lammeren-Venema, D, Legdeur, M C, van de Loosdrecht, A, Maertens, J, Kooy, M V M, Moors, I, Nijziel, M, van Obbergh, F, Oosterveld, M, Pabst, T, van der Poel, M, Sinnige, H, Spertini, O, Terpstra, W, Tick, L, van der Velden, W, Vekemans, M C, Vellenga, E, de Weerdt, O, Westerweel, P, Stüssi, G, van Norden, Y & Ossenkoppele, G 2021, ' Inferior outcome of addition of the aminopeptidase inhibitor tosedostat to standard intensive treatment for elderly patients with aml and high risk mds ', Cancers, vol. 13, no. 4, 672, pp. 1-11 . https://doi.org/10.3390/cancers13040672
Cancers, Vol. 13, no. 4, p. 672 [1-11] (2021)
Cancers, Vol 13, Iss 672, p 672 (2021)
Cancers, 13(4):672, 1-11. Multidisciplinary Digital Publishing Institute (MDPI)
Janssen, Jeroen; Löwenberg, Bob; Manz, Markus; Bargetzi, Mario; Biemond, Bart; Borne, Peter von dem; Breems, Dimitri; Brouwer, Rolf; Chalandon, Yves; Deeren, Dries; Efthymiou, Anna; Gjertsen, Bjørn-Tore; Graux, Carlos; Gregor, Michael; Heim, Dominik; Hess, Urs; Hoogendoorn, Mels; Jaspers, Aurelie; Jie, Asiong; Jongen-Lavrencic, Mojca; ... (2021). Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. Cancers, 13(4) MDPI AG 10.3390/cancers13040672
Cancers, 13, 4
Cancers, 13(4):672. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers, 13(4):672. MDPI AG
CANCERS

Simple Summary Treatment results of acute myeloid leukemia (AML) in elderly patients are unsatisfactory. We investigated in an open label randomized phase II study whether addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6c3557e55ce8459b851cd9c38536009
https://research.rug.nl/en/publications/b689d4dd-486c-4cc1-9c6b-e638c8aa76ce

Rituximab-PECC induction followed by

Autor: Pieternella J, Lugtenburg, Josee M, Zijlstra, Jeanette K, Doorduijn, Lara H, Böhmer, Mels, Hoogendoorn, Henriette W, Berenschot, Aart, Beeker, Nicole C, van der Burg-de Graauw, Harry C, Schouten, Yavuz M, Bilgin, Marie-Jose, Kersten, Harry R, Koene, Alexandra H E, Herbers, Daphne, de Jong, Nathalie, Hijmering, King H, Lam, Dana, Chiţu, Rolf E, Brouwer, Gustaaf W, van Imhoff

Publikováno v: British journal of haematologyReferences. 187(3)

Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after, or ineligible for, autologous stem cell transplantation (ASCT) have a dismal prognosis. This phase II study evaluated treatment with R-PECC (rituximab, prednisolone, etopo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::353f5512550baabc11a69b54080994f5
https://pubmed.ncbi.nlm.nih.gov/31290569